AngioDynamics, Inc. (ANGO): Price and Financial Metrics
ANGO Price/Volume Stats
| Current price | $6.31 | 52-week high | $11.38 |
| Prev. close | $6.37 | 52-week low | $5.26 |
| Day low | $6.25 | Volume | 596,500 |
| Day high | $6.42 | Avg. volume | 583,578 |
| 50-day MA | $5.91 | Dividend yield | N/A |
| 200-day MA | $7.08 | Market Cap | 252.75M |
ANGO Stock Price Chart Interactive Chart >
AngioDynamics, Inc. (ANGO) Company Bio
AngioDynamics designs, manufactures, and sells various medical, surgical, and diagnostic devices for vascular access, surgery, peripheral vascular disease, and oncology in the United States and internationally. The company was founded in 1988 and is based in Latham, New York.
Latest ANGO News From Around the Web
Below are the latest news stories about ANGIODYNAMICS INC that investors may wish to consider to help them evaluate ANGO as an investment opportunity.
AngioDynamics to Present at the J.P. Morgan Healthcare ConferenceLATHAM, N.Y., December 21, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan 42nd Annual Healthcare Conference at 9:00 |
Why AngioDynamics (ANGO) Outpaced the Stock Market TodayThe latest trading day saw AngioDynamics (ANGO) settling at $7.63, representing a +1.87% change from its previous close. |
AngioDynamics (ANGO) Stock Drops Despite Market Gains: Important Facts to NoteAngioDynamics (ANGO) closed at $6.91 in the latest trading session, marking a -0.72% move from the prior day. |
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024LATHAM, N.Y., December 07, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market open on Friday, January 5, 2024. The Company’s management will host a conference call at 8:00 a.m. ET the same |
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary EmbolismLATHAM, N.Y., December 07, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a clinical study aimed at evaluating the safety and efficacy of the Company’s Alp |
ANGO Price Returns
| 1-mo | 17.50% |
| 3-mo | 7.13% |
| 6-mo | -6.52% |
| 1-year | -30.51% |
| 3-year | -73.96% |
| 5-year | -68.81% |
| YTD | -19.52% |
| 2023 | -43.06% |
| 2022 | -50.07% |
| 2021 | 79.91% |
| 2020 | -4.25% |
| 2019 | -20.47% |
Continue Researching ANGO
Want to do more research on Angiodynamics Inc's stock and its price? Try the links below:Angiodynamics Inc (ANGO) Stock Price | Nasdaq
Angiodynamics Inc (ANGO) Stock Quote, History and News - Yahoo Finance
Angiodynamics Inc (ANGO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...